Search clinical trials for: BI 224436

Total 1228 results

Boehringer Ingelheim

Completed

Phase I Trial of BI 836845 for Various Solid Cancer

Neoplasms

Taiwan
Boehringer Ingelheim

Completed

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

Osteoarthritis

Germany
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Liposarcoma, Dedifferentiated

United States, Australia, Canada, United Kingdom, Japan, Brazil, Argentina
Boehringer Ingelheim

Recruiting

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

Kidney Disease, Chronic

United States, Belgium, Australia, Spain, Germany, France, Italy, New Zealand, United Kingdom, China, Ireland
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Bronchiectasis

Spain, United States, Denmark, Belgium, Korea, Republic of, Canada, Italy, Japan, Bulgaria, Australia, Latvia, Netherlands, United Kingdom, Germany, Israel, France, Hungary, Mexico, Greece, Poland, Turkey, Czechia, Portugal
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People

Healthy

Belgium
Boehringer Ingelheim

Terminated

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

Non-cystic Fibrosis Bronchiectasis

United Kingdom, Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Macular Edema

Spain, United Kingdom, Germany, Portugal, France, Belgium, Hungary, Greece
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Korea, Republic of, Japan
Boehringer Ingelheim

Completed

Investigation of Single Rising Doses of BI 685509

Healthy

Germany
Boehringer Ingelheim

Terminated

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia (HORNBILL)

Diabetic Retinopathy

United States, United Kingdom
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Northwell Health

Recruiting

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Prostate Cancer | Magnetic Resonance Imaging | Population at Risk

United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

United States, Japan, Canada
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Spain, Korea, Republic of, China, Israel, Germany, Japan, Singapore, Australia, United Kingdom, Austria, Netherlands, France, Portugal, Sweden, Italy, Belgium
Boehringer Ingelheim

Completed

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States, Germany, Sweden, Finland, Israel, Poland, Mexico, Croatia
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Borderline Personality Disorder

Spain, Germany, Sweden, United States, Mexico, Argentina, France, Poland, Australia, Belgium, Bulgaria, Czechia, Denmark, Italy, Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma

Asthma

Germany
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Terminated

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Healthy

Germany
Boehringer Ingelheim

Terminated

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

COVID-19

Spain, United States, Mexico, Brazil, Chile, Puerto Rico
Boehringer Ingelheim

Completed

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

Healthy

Germany
Medtronic Cardiac Rhythm and Heart Failure

Completed

SelectSecure 3830 Lead Imaging

Heart Diseases

United States
Boehringer Ingelheim

Withdrawn

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

3

Subscribe